

sPEER-REVIEW REPORT

Name of journal: World Journal of Psychiatry

Manuscript NO: 54597

Title: Pimavanserin for the treatment of psychosis in Alzheimer's disease: A systematic review.

Reviewer's code: 00784262

Position: Editorial Board

Academic degree: DSc, FRCP (C), MD

Professional title: Emeritus Professor, Professor

Reviewer's country: Canada

Author's country: United States

Manuscript submission date: 2020-02-13

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2020-03-14 01:49

Reviewer performed review: 2020-03-14 02:14

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is a well done, thorough review of the literature on a relatively new antipsychotic that has been used in the psychosis that sometimes accompanies Parkinson's Disease. The investigators reviewed its use in Alzheimer's Disease (AD). They found only one RCT and the article describes this one study in detail. Although this is a well done review, it is difficult to justify a review that reviews only one paper. The authors do include in the Discussion the use of the drug in Parkinson's Disease, which helps. To put some more meat into the review, I would suggest reviewing the use of antipsychotics in general in AD, including safety issues and then comparing these results with that of the one study of Pimavanserin.

Author response:

Noted and addressed in introduction and background.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Psychiatry

Manuscript NO: 54597

Title: Pimavanserin for the treatment of psychosis in Alzheimer's disease: A systematic review.

Reviewer's code: 02445209

Position: Editorial Board

Academic degree: N/A, MD, PhD

Professional title: Professor

Reviewer's country: Czech Republic

Author's country: United States

Manuscript submission date: 2020-02-13

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2020-03-16 05:24

Reviewer performed review: 2020-03-19 07:58

Review time: 3 Days and 2 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear authors, I have some comments on your manuscript. As of the title of your manuscript: Do you think that the label "A systematic review" is appropriate if you review only one clinical trial (with two published papers based on this trial)? I disagree with your statement that Alzheimer's dementia is the most prevalent form of dementia in the world. In my opinion, the most prevalent form of dementia is a mixed dementia (i.e. Alzheimer's + vascular component). You should comment on this in the Abstract as well as Introduction. You should give more details about the MMSE values in the patients in the trial (e.g. MMSE in pimavanserin group, in placebo group etc.). Best regards The reviewer

Author response:

Done- Literature review used in title.

Mixed dementia added in abstract and background (new reference, #2)

MMSE scores added (page 14 and page 18)

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Psychiatry

Manuscript NO: 54597

Title: Pimavanserin for the treatment of psychosis in Alzheimer's disease: A systematic review.

Reviewer's code: 03764910

Position: Editorial Board

Academic degree: MD, MSc, PhD

Professional title: Associate Professor

Reviewer's country: Japan

Author's country: United States

Manuscript submission date: 2020-02-13

Reviewer chosen by: Le Zhang

Reviewer accepted review: 2020-03-14 01:55

Reviewer performed review: 2020-03-21 16:06

Review time: 7 Days and 14 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The author attempted to clarify the effectiveness and safety of pimavanserin for psychotic patients with Alzheimer's disease with a systematic review. The methodology adopted in this review is standardized and properly structured. As a result, there has been only one study of placebo-controlled randomized trial found via comprehensive search. Because of limited number of trustworthy data, a meta analysis cannot be conducted in this research question. Thus, it should be concluded that the evidence of effectiveness of pimavanserin against AD psychosis is yet to be determined. The conclusion the author presented in this manuscript seems too optimistic.

Author response:

Done- abstract and conclusion changed

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No